TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Clinical trials for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOID CARDIOMYOPATHY trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Heart Drug's Real-World impact studied in korean patients
Disease control CompletedThis study looked at how well the medicine Tafamidis 61mg worked for Korean patients with a specific heart muscle disease called ATTR-CM. It observed 13 patients who were already prescribed this medicine in real-world settings, not as part of a controlled trial. The goal was to c…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Sponsor: Pfizer • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Heart drug safety checked in small indian patient group
Disease control CompletedThis study monitored the safety of the drug Tafamidis (VyndaMx®) in six Indian patients diagnosed with a serious heart condition called ATTR-CM. The condition is caused by a protein clumping in the heart, making it harder to pump. Researchers tracked any side effects patients exp…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Sponsor: Pfizer • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC